Max Planck-Bristol Centre for Minimal Biology

Locking down the SARS-CoV-2 spike Many efforts to develop therapies against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) are focused on the spike (S) protein trimer that binds to the host receptor. Structures of trimeric S protein show its receptor-binding domain in either an up or a down conformation. Toelzer et al. produced SARS-CoV-2 S in insect cells and determined the structure by cryo–electron microscopy. In their dataset, the closed form was predominant and was stabilized by binding linoleic acid, an essential fatty acid. A similar binding pocket appears to be present in previous highly pathogenic coronaviruses, and past studies suggested links between viral infection and fatty acid metabolism. The pocket could be exploited to develop inhibitors that trap S protein in the closed conformation. Science , this issue p. 725

ConspectusAlthough complex coacervate microdroplets derived from associative phase separation of counter-charged electrolytes have emerged as a broad platform for the bottom-up construction of membraneless, molecularly crowded protocells, the absence of an enclosing membrane limits the construction of more sophisticated artificial cells and their use as functional cytomimetic materials. To address this problem, we and others have recently developed chemical-based strategies for the membranization of preformed coacervate microdroplets. In this Account, we review our recent work on diverse coacervate systems using a range of membrane building blocks and assembly processes. First, we briefly introduce the unusual nature of the coacervate/water interface, emphasizing the ultralow interfacial tension and broad interfacial width as physiochemical properties that require special attention in the judicious design of membranized coacervate microdroplets. Second, we classify membrane assembly into two different approaches: (i) interfacial self-assembly by using diverse surface-active building blocks such as molecular amphiphiles (fatty acids, phospholipids, block copolymers, protein–polymer conjugates) or nano- and microscale objects (liposomes, nanoparticle surfactants, cell fragments, living cells) with appropriate wettability; and (ii) coacervate droplet-to-vesicle reconfiguration by employing auxiliary surface reconstruction agents or triggering endogenous transitions (self-membranization) under nonstoichiometric (charge mismatched) conditions. We then discuss the key cytomimetic behaviors of membranized coacervate-based model protocells. Customizable permeability is achieved by synergistic effects operating between the molecularly crowded coacervate interior and surrounding membrane. In contrast, metabolic-like endogenous reactivity, diffusive chemical signaling, and collective chemical operations occur specifically in protocell networks comprising diverse populations of membranized coacervate microdroplets. In each case, these cytomimetic behaviors can give rise to functional microscale materials capable of promising cell-like applications. For example, immobilizing spatially segregated enzyme-loaded phospholipid-coated coacervate protocells in concentrically tubular hydrogels delivers prototissue-like bulk materials that generate nitric oxide in vitro, enabling platelet deactivation and inhibition of blood clot formation. Alternatively, therapeutic protocells with in vivo vasoactivity, high hemocompatibility, and increased blood circulation times are constructed by spontaneous assembly of hemoglobin-containing cell-membrane fragments on the surface of enzyme-loaded coacervate microdroplets. Higher-order properties such as artificial endocytosis are achieved by using nanoparticle-caged coacervate protocell hosts that selectively and actively capture guest nano- and microscale objects by responses to exogenous stimuli or via endogenous enzyme-mediated reactions. Finally, we discuss the current limitations in the design and programming of membranized coacervate microdroplets, which may help to guide future directions in this emerging research area. Taken together, we hope that this Account will inspire new advances in membranized coacervate microdroplets and promote their application in the development of integrated protocell models and functional cytomimetic materials.

The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) causes a broad range of clinical responses including prominent microvascular damage. The capacity of SARS-CoV-2 to infect vascular cells is still debated. Additionally, the SARS-CoV-2 Spike (S) protein may act as a ligand to induce non-infective cellular stress. We tested this hypothesis in pericytes (PCs), which are reportedly reduced in the heart of patients with severe coronavirus disease-2019 (COVID-19). Here we newly show that the in vitro exposure of primary human cardiac PCs to the SARS-CoV-2 wildtype strain or the α and δ variants caused rare infection events. Exposure to the recombinant S protein alone elicited signalling and functional alterations, including: (1) increased migration, (2) reduced ability to support endothelial cell (EC) network formation on Matrigel, (3) secretion of pro-inflammatory molecules typically involved in the cytokine storm, and (4) production of pro-apoptotic factors causing EC death. Next, adopting a blocking strategy against the S protein receptors angiotensin-converting enzyme 2 (ACE2) and CD147, we discovered that the S protein stimulates the phosphorylation/activation of the extracellular signal-regulated kinase 1/2 (ERK1/2) through the CD147 receptor, but not ACE2, in PCs. The neutralisation of CD147, either using a blocking antibody or mRNA silencing, reduced ERK1/2 activation, and rescued PC function in the presence of the S protein. Immunoreactive S protein was detected in the peripheral blood of infected patients. In conclusion, our findings suggest that the S protein may prompt PC dysfunction, potentially contributing to microvascular injury. This mechanism may have clinical and therapeutic implications.

Protein structures are essential to understanding cellular processes in molecular detail. While advances in artificial intelligence revealed the tertiary structure of proteins at scale, their quaternary structure remains mostly unknown. We devise a scalable strategy based on AlphaFold2 to predict homo-oligomeric assemblies across four proteomes spanning the tree of life. Our results suggest that approximately 45% of an archaeal proteome and a bacterial proteome and 20% of two eukaryotic proteomes form homomers. Our predictions accurately capture protein homo-oligomerization, recapitulate megadalton complexes, and unveil hundreds of homo-oligomer types, including three confirmed experimentally by structure determination. Integrating these datasets with omics information suggests that a majority of known protein complexes are symmetric. Finally, these datasets provide a structural context for interpreting disease mutations and reveal coiled-coil regions as major enablers of quaternary structure evolution in human. Our strategy is applicable to any organism and provides a comprehensive view of homo-oligomerization in proteomes.

The circadian rhythm generates out-of-equilibrium metabolite oscillations that are controlled by feedback loops under light/dark cycles. Here we describe a non-equilibrium nanosystem comprising a binary population of enzyme-containing polymersomes capable of light-gated chemical communication, controllable feedback and coupling to macroscopic oscillations. The populations consist of esterase-containing polymersomes functionalized with photo-responsive donor-acceptor Stenhouse adducts (DASA) and light-insensitive semipermeable urease-loaded polymersomes. The DASA-polymersome membrane becomes permeable under green light, switching on esterase activity and decreasing the pH, which in turn initiates the production of alkali in the urease-containing population. A pH-sensitive pigment that absorbs green light when protonated provides a negative feedback loop for deactivating the DASA-polymersomes. Simultaneously, increased alkali production deprotonates the pigment, reactivating esterase activity by opening the membrane gate. We utilize light-mediated fluctuations of pH to perform non-equilibrium communication between the nanoreactors and use the feedback loops to induce work as chemomechanical swelling/deswelling oscillations in a crosslinked hydrogel. We envision possible applications in artificial organelles, protocells and soft robotics.

Although the complexity of synthetic cells has continued to increase in recent years, chemical communication between protocell models and living organisms remains a key challenge in bottom-up synthetic biology and bioengineering. In this Review, we discuss how communication channels and modes of signal processing can be established between living cells and cytomimetic agents such as giant unilamellar lipid vesicles, proteinosomes, polysaccharidosomes, polymer-based giant vesicles and membrane-less coacervate micro-droplets. We describe three potential modes of chemical communication in consortia of synthetic and living cells based on mechanisms of distributed communication and signal processing, physical embodiment and nested communication, and network-based contact-dependent communication. We survey the potential for applying synthetic cell/living cell communication systems in biomedicine, including the in situ production of therapeutics and development of new bioreactors. Finally, we present a short summary of our findings.

, direct the folding and assembly of amphipathic α helices into bundles. However, many different bundles are possible: they can have two or more helices (different oligomers); the helices can have parallel, antiparallel, or mixed arrangements (different topologies); and the helical sequences can be the same (homomers) or different (heteromers). Thus, sequence-to-structure relationships must be present within the hpphppp repeats to distinguish these states. I discuss the current understanding of this problem at three levels: first, physics gives a parametric framework to generate the many possible coiled-coil backbone structures. Second, chemistry provides a means to explore and deliver sequence-to-structure relationships. Third, biology shows how coiled coils are adapted and functionalized in nature, inspiring applications of coiled coils in synthetic biology. I argue that the chemistry is largely understood; the physics is partly solved, though the considerable challenge of predicting even relative stabilities of different coiled-coil states remains; but there is much more to explore in the biology and synthetic biology of coiled coils.

Controlling the dynamics of mixed communities of cell-like entities (protocells) provides a step toward the development of higher-order cytomimetic behaviors in artificial cell consortia. In this paper, we develop a caged protocell model with a molecularly crowded coacervate interior surrounded by a non-cross-linked gold (Au)/poly(ethylene glycol) (PEG) nanoparticle-jammed stimuli-responsive membrane. The jammed membrane is unlocked by either exogenous light-mediated Au/PEG dissociation at the Au surface or endogenous enzyme-mediated cleavage of a ketal linkage on the PEG backbone. The membrane assembly/disassembly process is used for the controlled and selective uptake of guest protocells into the caged coacervate microdroplets as a path toward an all-water model of triggerable transmembrane uptake in synthetic protocell communities. Active capture of the guest protocells stems from the high sequestration potential of the coacervate interior such that tailoring the surface properties of the guest protocells provides a rudimentary system of protocell sorting. Our results highlight the potential for programming surface-contact interactions between artificial membrane-bounded compartments and could have implications for the development of protocell networks, storage and delivery microsystems, and microreactor technologies.

We investigate binding of linoleate and other potential ligands to the recently discovered fatty acid binding site in the SARS-CoV-2 spike protein, using docking and molecular dynamics simulations. Simulations suggest that linoleate and dexamethasone stabilize the locked spike conformation, thus reducing the opportunity for ACE2 interaction. In contrast, cholesterol may expose the receptor-binding domain by destabilizing the closed structure, preferentially binding to a different site in the hinge region of the open structure. We docked a library of FDA-approved drugs to the fatty acid site using an approach that reproduces the structure of the linoleate complex. Docking identifies steroids (including dexamethasone and vitamin D); retinoids (some known to be active in vitro, and vitamin A); and vitamin K as potential ligands that may stabilize the closed conformation. The SARS-CoV-2 spike fatty acid site may bind a diverse array of ligands, including dietary components, and therefore provides a promising target for therapeutics or prophylaxis.

The spontaneous self-assembly of multicellular ensembles into living materials with synergistic structure and function remains a considerable challenge in biotechnology and synthetic biology. Here, we exploit the aqueous two-phase separation of dextran-in-PEG emulsion micro-droplets for the capture, spatial organization and immobilization of algal cells or algal/bacterial cell communities to produce discrete multicellular spheroids capable of both aerobic (oxygen producing) and hypoxic (hydrogen producing) photosynthesis in daylight under air. We show that localized oxygen depletion results in hydrogen production from the core of the algal microscale reactor, and demonstrate that enhanced levels of hydrogen evolution can be achieved synergistically by spontaneously enclosing the photosynthetic cells within a shell of bacterial cells undergoing aerobic respiration. Our results highlight a promising droplet-based environmentally benign approach to dispersible photosynthetic microbial micro-reactors comprising segregated cellular micro-niches with dual functionality, and provide a step towards photobiological hydrogen production under aerobic conditions.

The Commander complex is required for endosomal recycling of diverse transmembrane cargos and is mutated in Ritscher-Schinzel syndrome. It comprises two sub-assemblies: Retriever composed of VPS35L, VPS26C, and VPS29; and the CCC complex which contains twelve subunits: COMMD1-COMMD10 and the coiled-coil domain-containing (CCDC) proteins CCDC22 and CCDC93. Combining X-ray crystallography, electron cryomicroscopy, and in silico predictions, we have assembled a complete structural model of Commander. Retriever is distantly related to the endosomal Retromer complex but has unique features preventing the shared VPS29 subunit from interacting with Retromer-associated factors. The COMMD proteins form a distinctive hetero-decameric ring stabilized by extensive interactions with CCDC22 and CCDC93. These adopt a coiled-coil structure that connects the CCC and Retriever assemblies and recruits a 16th subunit, DENND10, to form the complete Commander complex. The structure allows mapping of disease-causing mutations and reveals the molecular features required for the function of this evolutionarily conserved trafficking machinery.

Extracellular vesicles (EVs) are fundamental for intercellular communication and influence nearly every process in cell physiology. However, because of their intricate molecular complexity, quantitative knowledge on their signaling mechanisms is missing, particularly impeding their therapeutic application. We used a complementary and quantitative engineering approach based on sequential synthetic bottom-up assembly of fully functional EVs with precisely controlled lipid, protein, and RNA composition. We show that the functionalities of synthetic EVs are analogous to natural EVs and demonstrate their programmable therapeutic administration for wound healing and neovascularization therapy. We apply transcriptome profiling to systematically decode synergistic effects between individual EV constituents, enabling analytical dissection and a fundamental understanding of EV signaling.

Nanomedicine has demonstrated the potential of nanotechnology in treating diseases by selectively targeting pathogenic cells and releasing their cargo on site, but the complexity of molecular engineering such drug-delivery vehicles impedes their broad application and clinical translation. New methodologies to generate more advanced and intelligent systems are required.Bottom-up synthetic biology, empowered by microfluidics, allows the conception of multifunctional cell-mimicking structures – such as synthetic exosomes – that showcase its ability to create sophisticated systems.Recently, considerable progress has been made towards the assembly of complex structures that can dynamically release therapeutics, sustain protein biosynthesis, and sense and interact with the nearby environment. These functionalities will propel the creation of advanced drug-delivery platforms. Creating a magic bullet that can selectively kill cancer cells while sparing nearby healthy cells remains one of the most ambitious objectives in pharmacology. Nanomedicine, which relies on the use of nanotechnologies to fight disease, was envisaged to fulfill this coveted goal. Despite substantial progress, the structural complexity of therapeutic vehicles impedes their broad clinical application. Novel modular manufacturing approaches for engineering programmable drug carriers may be able to overcome some fundamental limitations of nanomedicine. We discuss how bottom-up synthetic biology principles, empowered by microfluidics, can palliate current drug carrier assembly limitations, and we demonstrate how such a magic bullet could be engineered from the bottom up to ultimately improve clinical outcomes for patients. Creating a magic bullet that can selectively kill cancer cells while sparing nearby healthy cells remains one of the most ambitious objectives in pharmacology. Nanomedicine, which relies on the use of nanotechnologies to fight disease, was envisaged to fulfill this coveted goal. Despite substantial progress, the structural complexity of therapeutic vehicles impedes their broad clinical application. Novel modular manufacturing approaches for engineering programmable drug carriers may be able to overcome some fundamental limitations of nanomedicine. We discuss how bottom-up synthetic biology principles, empowered by microfluidics, can palliate current drug carrier assembly limitations, and we demonstrate how such a magic bullet could be engineered from the bottom up to ultimately improve clinical outcomes for patients. Paul Ehrlich, considered to be the pioneer and founder of modern chemotherapy, envisaged a therapeutic capable of directly interreacting with its intended disease-causing cellular structure while remaining harmless to the surrounding healthy cell population. Depicted as a magic bullet, his idea has greatly influenced and fascinated various fields of science for more than a century [1.Strebhardt K. Ullrich A. Paul Ehrlich's magic bullet concept: 100 years of progress.Nat. Rev. Cancer. 2008; 8: 473-480Crossref PubMed Scopus (747) Google Scholar]. Among them, the field of nanomedicine (see Glossary) – which relies on nanotechnologies to improve passive and active accumulation of drugs nearby target pathogens or cell populations – was expected to achieve this highly coveted goal. Despite its major focus on oncology, nanomedicine has also triggered the engineering of an arsenal of novel nanotechnologies and functionalization strategies. Overall, these innovations have resulted in a variety of enhanced bio- and physico-chemical properties for inorganic-, polymer-, and lipid-based nanometric carriers. Despite recent progress, nanomedicine is often synonymous with modest clinical translation and remains the focus of significant debate (as reviewed extensively [2.Björnmalm M. science and cancer PubMed Scopus Google or PubMed Scopus Google cancer PubMed Scopus Google of A. and enhanced accumulation in of in Google and in a of for of PubMed Scopus Google M. and in PubMed Scopus Google and most A. and the clinical translation of PubMed Scopus Google are and in the of drugs in the remains will to be overcome to achieve and of carriers. of may be to as and These are by the of target and release which the A. cancer with Rev. Cancer. Scopus Google Scholar]. targeting is and in and also in or the targeting of is highly are expected to the targeting of with an the PubMed Scopus Google as drug carrier for PubMed Scopus Google M. of with for enhanced PubMed Scopus Google or the in the or more and to Rev. Google Scholar]. this may be by engineering the properties of the carrier such as molecular and properties achieve and the carrier to various to and selectively interact with the cellular – such as cancer cells – that are by a of healthy cellular this to – such as or – are to of the carrier with the target cell its and ultimately release its molecular of targeting the in most accumulation of in the disease-causing cells (see in targeting has on that have of and These which are for the and to an in the passive accumulation of therapeutic carriers in these targeting of these the of and that to be considered a drug-delivery the site, a drug-delivery have a the that the carrier be able to the of the carrier most the is the to in the has been made for the that of the target of to Rev. Scopus Google Scholar]. the of a drug carrier with the and its and accumulation its towards a therapeutic for and PubMed Scopus Google of for to drug PubMed Scopus Google Scholar]. These and of these to be to and therapeutic in the of cancer to for and to be to target cancer on PubMed Scopus Google A. of and on Rev. PubMed Scopus Google the targeting of – such as the and the – is highly Despite the that vehicles to various also that be than properties K. of on of by PubMed Scopus Google on by in of PubMed Scopus Google Scholar]. the of carriers the was by such as of drugs the PubMed Scopus Google K. of to drug the PubMed Scopus Google or by and molecular and PubMed Scopus Google Scholar]. to targeting to the and by their targeting for and PubMed Scopus Google Scholar]. These the of such as and of and targeting up and more to cell to be as of the carrier to selectively target disease-causing which are by of healthy is by various molecular such as or on the with the molecular the may in a of the carrier in to the target cell population. this will the or of the carrier with the target cell the carrier release its therapeutic to the drug carrier be molecular of the is often and by the cellular Google Scholar]. in to cells a in the a in the potential to by of the and of recent have on drug carrier to that as a of M. on and in PubMed Scopus Google M. for drug PubMed Scopus Google to for enhanced PubMed Scopus Google Scholar]. triggered by the can the of the can the of the the ability to release its cargo on M. on and in PubMed Scopus Google M. and in drug a PubMed Scopus Google or its to with the cancer cell of in PubMed Scopus Google Scholar]. allows the of and drug to healthy carrier targeting the release of its cargo and with the target for or of the drug is directly by its to overcome the of in and – that the of and of and potential clinical of 8: Scopus Google Scholar]. carriers to to to healthy and and in the environment. targeting the in most accumulation of in the disease-causing cells (see in targeting has on that have of and These which are for the and to an in the passive accumulation of therapeutic carriers in these targeting of these the of and that to be considered a drug-delivery the site, a drug-delivery have a the that the carrier be able to the of the carrier most the is the to in the has been made for the that of the target of to Rev. Scopus Google Scholar]. the of a drug carrier with the and its and accumulation its towards a therapeutic for and PubMed Scopus Google of for to drug PubMed Scopus Google Scholar]. These and of these to be to and therapeutic in the of cancer to for and to be to target cancer on PubMed Scopus Google A. of and on Rev. PubMed Scopus Google Scholar]. the targeting of – such as the and the – is highly Despite the that vehicles to various also that be than properties K. of on of by PubMed Scopus Google on by in of PubMed Scopus Google Scholar]. the of carriers the was by such as of drugs the PubMed Scopus Google K. of to drug the PubMed Scopus Google or by and molecular and PubMed Scopus Google Scholar]. to targeting to the and by their targeting for and PubMed Scopus Google Scholar]. These the of such as and targeting up and more to cell to be as of the carrier to selectively target disease-causing which are by of healthy is by various molecular such as or on the with the molecular the may in a of the carrier in to the target cell population. this will the or of the carrier with the target cell the carrier release its therapeutic to the drug carrier be molecular of the is often and by the cellular Google Scholar]. in to cells a in the a in the potential to by of the and of recent have on drug carrier to that as a of M. on and in PubMed Scopus Google M. for drug PubMed Scopus Google to for enhanced PubMed Scopus Google Scholar]. triggered by the can the of the can the of the the ability to release its cargo on M. on and in PubMed Scopus Google M. and in drug a PubMed Scopus Google or its to with the cancer cell of in PubMed Scopus Google Scholar]. allows the of and drug to healthy carrier targeting the release of its cargo and with the target for or of the drug is directly by its to overcome the of in and – that the of and of and potential clinical of 8: Scopus Google Scholar]. carriers to to to healthy and and in the environment. a remains is the current focus on to improve the clinical of drug-delivery on the that a of have to cancer the their in of to Rev. Scopus Google as as the structural and complexity of the that to be overcome for drug the to cancer cells in PubMed Scopus Google the to cancer PubMed Scopus Google nanomedicine to Rev. PubMed Scopus Google Scholar]. a of a of a potential for targeting of the by to and of from to in for the of PubMed Scopus Google K. of for the 2008; PubMed Scopus Google Scholar]. These that such as have potential for of lipid-based vehicles is that the can be by various or while also for and and of for cargo PubMed Scopus Google Scholar]. recent have demonstrated that lipid-based can interact with cells and their assembly of synthetic by PubMed Scopus Google as as directly release the for molecular to the cellular PubMed Scopus Google Scholar]. These that can be by and interact with the of to and systems up for the of more advanced carriers. for this ambitious is that the carriers to have a passive release of its cargo and the and of by the PubMed Scopus Google Scholar]. these cells may the drug-delivery to their ability to and interact with the and by as carriers. the use of or systems to has a focus of towards more systems have the use of on cell structures or on synthetic to improve drug-delivery recent innovations in the field of bottom-up synthetic biology – have been – cell could be engineered to improve drug a from to also the of that the of and is to complex and of and of for cargo PubMed Scopus Google assembly of synthetic by PubMed Scopus Google K. towards bottom-up of multifunctional synthetic PubMed Scopus Google of a for drug PubMed Scopus Google M. bottom-up assembly of synthetic cells by PubMed Google Scholar]. the potential of bottom-up synthetic biology for the of advanced drug-delivery carriers. We how systems can and improve drug we that bottom-up synthetic biology to generate synthetic systems with and properties for advanced drug We also the of complex systems with various and the and that these overcome clinical translation. we a on the potential of the advanced bottom-up assembly of lipid-based carriers for are lipid-based that are by various cell and from 100 to in have significant as therapeutic vehicles of for drug – on and PubMed Scopus Google and for on and PubMed Scopus Google cancer by of PubMed Scopus Google to their in and their in various of can achieve accumulation and to cells and drug the of in cancer PubMed Scopus Google of to overcome in cancer PubMed Scopus Google Scholar]. from the of advanced in of and exosomes by synthetic with exosomes for drug PubMed Scopus Google Scholar]. various such as and (see in the from application was with cancer targeting and cell and demonstrated the of the properties of for drug to cells of their drug-delivery PubMed Scopus Google Scholar]. that the properties of by cells – in – on the of the cell environment. from cells from cells in a to of in to targeting by systems also on cell is a of is a to and and an with and that these can as a by the a of was the to drug with a PubMed Scopus Google Scholar]. Overall, this potential to the for drugs in on the assembly of various of can target cell by a and of PubMed Scopus Google Scholar]. and this by in the of by of to selectively of cancer cells with the with PubMed Scopus Google Scholar]. These the of properties and and properties various on the targeting and drug-delivery These can be drug-delivery systems by as and and and these their broad clinical translation M. and in exosomes for cancer PubMed Scopus Google Scholar]. in to selectively targeting cells and the drug-delivery systems will to be able to sense and to in their drug release – a to as intelligent and release of the of a bottom-up can be by the of multifunctional synthetic systems with and properties for advanced drug modular engineering for the bottom-up assembly of synthetic cells can be to more complex systems that can the of cargo on and an synthetic cell that is capable of as a of the cells for PubMed Scopus Google Scholar]. of assembly was to create with and to the synthetic the by to a in the which in the can with which is the of the the of by has an ability to in in a was by and a protein in to directly and release their cells therapeutic Scopus Google Scholar]. of in their such as and the therapeutic synthetic cells could and release the of cancer cells in and also in the directly the therapeutic synthetic cell than may be to the of the protein directly in the synthetic cells or to the release of protein in disease-causing novel which synthetic biology and drug with the potential of advanced carriers to directly the and bottom-up assembly of These for the release of molecular such as in to a synthetic in PubMed Scopus Google a synthetic may be as the of in the to the of a from fundamental and as to the assembly of a to or may be as fundamental to generate various synthetic – and their use be to their properties can be engineered to various the field of drug these synthetic therapeutic their and release their or the is and functionalities are the synthetic to and in the of complex synthetic the of and in an to the release of as a of synthetic cell – also as a – is a of a cell that to cellular functionalities by in a These may and or to sustain to to the to and and with the and towards cells from the bottom PubMed Scopus Google Scholar]. to synthetic synthetic cells the of – or – by various to that be by synthetic synthetic cells are able to molecular from their to sustain their in and PubMed Scopus Google Scholar]. by of the molecular can be and in to in the of the synthetic by these synthetic cells to drug release of can be for drug a synthetic may be as the of in the to the of a from fundamental and as to the assembly of a to or may be as fundamental to generate various synthetic – and their use be to their properties can be engineered to various the field of drug these synthetic therapeutic their and release their or the is and functionalities are the synthetic to and in the of complex synthetic the of and in an to the release of as a of synthetic cell – also as a – is a of a cell that to cellular functionalities by in a These may and or to sustain to to the to and and with the and towards cells from the bottom PubMed Scopus Google Scholar]. to synthetic synthetic cells the of – or – by various to that be by synthetic synthetic cells are able to molecular from their to sustain their in and PubMed Scopus Google Scholar]. by of the molecular can be and in to in the of the synthetic by these synthetic cells to drug release of can be for drug to the ability to sense and to their advanced drug-delivery systems will to overcome (see on for will and the of and with and that can dynamically by sustain and in a PubMed Scopus Google Scholar]. These and to with to achieve is an for of and the of directly the to by an M. bottom-up assembly of synthetic cells by PubMed Google Scholar]. also that synthetic cells capable of and to the by with the to an These synthetic cells showcase the potential of the bottom-up to complex systems that are to such as to and to create with their environment. of bottom-up synthetic biology in the and of the of of various can be by and assembly the ability to generate with various the of properties such as and M. bottom-up assembly of synthetic cells by PubMed Google K. assembly of complex synthetic 8: PubMed Scopus Google Scholar]. allows the of of active the of the and assembly of systems and of for cargo PubMed Scopus Google M. bottom-up assembly of synthetic cells by PubMed Google K. assembly of complex synthetic 8: PubMed Scopus Google of lipid-based and PubMed Google Scholar]. the of an of PubMed Scopus Google the of in and the use of or a synthetic in PubMed Scopus Google cells as with PubMed Scopus Google cells with cells as PubMed Scopus Google A. of the for of PubMed Scopus Google and PubMed Scopus Google Scholar]. this can complex protein cells therapeutic Scopus Google Scholar]. is an assembly could to the also allows the of assembly of PubMed Google of synthetic PubMed Google Scholar]. is also with in which are with and PubMed Scopus Google Scholar]. the assembly of a of the or the of assembly of as cell PubMed Scopus Google Scholar]. of the is in for of for of was for one of the to the the or from the to the cells for PubMed Scopus Google release in and PubMed Scopus Google a for of PubMed Scopus Google of the in PubMed Scopus Google cells therapeutic Scopus Google a synthetic in PubMed Scopus Google of PubMed Scopus Google cells as with PubMed Scopus Google cells with cells as PubMed Scopus Google A. of the for of PubMed Scopus Google and PubMed Scopus Google and or assembly of PubMed Google and PubMed Scopus Google assembly of as cell PubMed Scopus Google of in PubMed Scopus Google with PubMed Scopus Google to or of synthetic PubMed Google assembly on PubMed Scopus Google of PubMed Scopus Google for synthetic of from in a PubMed Scopus Google a for the assembly of and PubMed Scopus Google M. for drug PubMed Scopus Google K. for the of active PubMed Google and and for and and of for cargo PubMed Scopus Google assembly of synthetic by PubMed Scopus Google M. bottom-up assembly of synthetic cells by PubMed Google K. assembly of complex synthetic 8: PubMed Scopus Google of lipid-based and PubMed Google and and to sustain and in a PubMed Scopus Google in to and PubMed Google was for one of the to the the or from the to the in a in the of the of a to the the of surrounding the the of potential that can the of the and the use of to and the of in a and PubMed Scopus Google assembly of as cell PubMed Scopus Google of in PubMed Scopus Google from PubMed Scopus Google Scholar]. the use of as an of the may be with of cargo to its with PubMed Scopus Google Scholar]. an that is with and has in and of to the of assembly on PubMed Scopus Google of PubMed Scopus Google Scholar]. to as assembly this the of to in directly on a these recent on the use of an of such as or These the use of as a an and a on as the and for synthetic of from in a PubMed Scopus Google Scholar]. the their on an by of than the to use to the most have an of the is to and in the of microfluidics, the of on a was to a of to and PubMed Scopus Google Scholar]. the of the on the properties and of the will to be with to therapeutic a a recent by to by that the of a on the of in the to by M. of and in PubMed Scopus Google Scholar]. for carrier assembly to complex lipid-based multifunctional targeting and from the bottom-up the can be to advanced drug-delivery systems the of for the of and protein cells with cells as PubMed Scopus Google of and in PubMed Scopus Google or of by PubMed Scopus Google but also to create that complex such as and that in assembly of PubMed Google of synthetic PubMed Google Scholar]. for can be by cells therapeutic Scopus Google and such as can be a can be by and to achieve and M. bottom-up assembly of synthetic cells by PubMed Google Scholar]. can be a by microfluidics, a that allows the and of to be assembly of as cell PubMed Scopus Google Scholar]. the and of drug carriers that the and of can be by such as cell on PubMed Scopus Google for the of to microfluidics, which the of various in a allows the of the of such as or These can as and have in various various a to a variety of and M. bottom-up assembly of synthetic cells by PubMed Google a for the of with PubMed Scopus Google a to the of the of various and with of an in PubMed Scopus Google a to improve and molecular the in with a Google a to on various such as cell on PubMed Scopus Google or of PubMed Scopus Google a releasing to the from the an by an field of with a of PubMed Scopus Google or by a passive structure M. bottom-up assembly of synthetic cells by PubMed Google and a or that the of a of lipid-based and PubMed Google of for PubMed Scopus Google Scholar]. to the various of microfluidics, – which in to – is with the use of assembly of as cell PubMed Scopus Google Scholar]. is to generate and complex from a PubMed Scopus Google Scholar]. to microfluidics, which the of various in a allows the of the of such as or These can as and have in various various a to a variety of and M. bottom-up assembly of synthetic cells by PubMed Google a for the of with PubMed Scopus Google a to the of the of various and with of an in PubMed Scopus Google a to improve and molecular the in with a Google a to on various such as cell on PubMed Scopus Google or of PubMed Scopus Google a releasing to the from the an by an field of with a of PubMed Scopus Google or by a passive structure M. bottom-up assembly of synthetic cells by PubMed Google and a or that the of a of lipid-based and PubMed Google of for PubMed Scopus Google Scholar]. to the various of microfluidics, – which in to – is with the use of assembly of as cell PubMed Scopus Google Scholar]. is to generate and complex from a PubMed Scopus Google Scholar]. Nanomedicine has novel for drug towards pathogens and disease-causing these carriers their and functionalization with a of to achieve drug These engineering the of and novel to and by the and of advanced drug carriers with and properties can be by bottom-up synthetic biology and cellular functionalities – such as protein and release of – novel carriers can achieve release of empowered by microfluidics, the and assembly of multifunctional systems can be with (see on the of release and the properties of the molecular cargo can be engineered to release that therapeutic systems to to the cellular the release of a towards therapeutic and in These to as a to improve drug of A. the of drugs PubMed Scopus Google Scholar]. to the in by of to a significant in the of surrounding the drug – by of the – was by these recent we that the release of various can and a potential from to in of the and the clinical of drug carriers has been use of to and these advanced carriers will such by and will be on to or a of the of and the of the properties of the such as and to be is have been to improve drug the of these may clinical translation. assembly of systems novel synthetic will to of the of lipid-based carriers be in could drug but also drugs that are in of have more complex and therapeutics, from molecular PubMed Scopus Google to of the PubMed Scopus Google and therapeutic M. therapeutic – a on the of cancer PubMed Scopus Google Scholar]. systems drug are also more to as drug in the target the of the to create vehicles that have cargo for to more complex systems by cells a for the of carriers is to that of cells the ability to interact and kill up target to to for and of we systems that complex and in a a could be engineered to their molecular and a could directly an in or could be from the of the for and a for and the could modern can we generate synthetic systems complexity is to that of how can we these systems towards advanced drug-delivery bottom-up synthetic biology to create a synthetic these synthetic properties and cellular as bottom-up synthetic biology and for by and of therapeutic use of to to be to their and their in or synthetic palliate the for and their these be current for of advanced therapeutic can we generate synthetic systems complexity is to that of how can we these systems towards advanced drug-delivery bottom-up synthetic biology to create a synthetic these synthetic properties and cellular as bottom-up synthetic biology and for by and of therapeutic use of to to be to their and their in or synthetic palliate the for and their these be current for of advanced therapeutic from the of and of – and the which is by the and the also the the of the and the is the the of and of the the of the of the from the and the to is the the of is for its an field that to create cellular the assembly of molecular that the and of to in an carrier These the of various to with a of that are by various cell to the of their exosomes a variety of and – such as and – from their cellular the such as and and and structures to exosomes as drug PubMed Google Scholar]. molecular exosomes the ability to in and the and of These in of the of and their in a variety of These a carriers for drug-delivery lipid-based that are as an a that relies on the of in a or the use of to various the as a broad nanomedicine the use of various of nanotechnology to or a of to as but nanomedicine has significant in the field of to the enhanced and properties by as and that with an and an or can be in the of a to their with can be in the to lipid-based or by the and

The design and construction of synthetic prototissues from integrated assemblies of artificial protocells is an important challenge for synthetic biology and bioengineering. Here we spatially segregate chemically communicating populations of enzyme-decorated phospholipid-enveloped polymer/DNA coacervate protocells in hydrogel modules to construct a tubular prototissue-like vessel capable of modulating the output of bioactive nitric oxide (NO). By decorating the protocells with glucose oxidase, horseradish peroxidase or catalase and arranging different modules concentrically, a glucose/hydroxyurea dual input leads to logic-gate signal processing under reaction-diffusion conditions, which results in a distinct NO output in the internal lumen of the model prototissue. The NO output is exploited to inhibit platelet activation and blood clot formation in samples of plasma and whole blood located in the internal channel of the device, thereby demonstrating proof-of-concept use of the prototissue-like vessel for anticoagulation applications. Our results highlight opportunities for the development of spatially organized synthetic prototissue modules from assemblages of artificial protocells and provide a step towards the organization of biochemical processes in integrated micro-compartmentalized media, micro-reactor technology and soft functional materials.

Recent advances in de novo protein design have delivered a diversity of discrete de novo protein structures and complexes. A new challenge for the field is to use these designs directly in cells to intervene in biological processes and augment natural systems. The bottom-up design of self-assembled objects such as microcompartments and membraneless organelles is one such challenge. Here we describe the design of genetically encoded polypeptides that form membraneless organelles in Escherichia coli. To do this, we combine de novo α-helical sequences, intrinsically disordered linkers and client proteins in single-polypeptide constructs. We tailor the properties of the helical regions to shift protein assembly from arrested assemblies to dynamic condensates. The designs are characterized in cells and in vitro using biophysical methods and soft-matter physics. Finally, we use the designed polypeptide to co-compartmentalize a functional enzyme pair in E. coli, improving product formation close to the theoretical limit.

Collective decision making by living cells is facilitated by exchange of diffusible signals where sender cells release a chemical signal that is interpreted by receiver cells. A variety of nonliving artificial cell models have been developed in recent years that mimic various aspects of diffusion-based intercellular communication. However, localized secretion of diffusive signals from individual protocells, which is critical for mimicking biological sender-receiver systems, has remained challenging to control precisely. Here, we engineer light-responsive, DNA-encoded sender-receiver architectures, where protein-polymer microcapsules act as cell mimics and molecular communication occurs through diffusive DNA signals. We prepare spatial distributions of sender and receiver protocells using a microfluidic trapping array and set up a signaling gradient from a single sender cell using light, which activates surrounding receivers through DNA strand displacement. Our systematic analysis reveals how the effective signal range of a single sender is determined by various factors including the density and permeability of receivers, extracellular signal degradation, signal consumption, and catalytic regeneration. In addition, we construct a three-population configuration where two sender cells are embedded in a dense array of receivers that implement Boolean logic and investigate spatial integration of nonidentical input cues. The results offer a means for studying diffusion-based sender-receiver topologies and present a strategy to achieve the congruence of reaction-diffusion and positional information in chemical communication systems that have the potential to reconstitute collective cellular patterns.

Bottom-up synthetic biology has directed most efforts toward the construction of artificial compartmentalized systems that recreate living cell functions in their mechanical, morphological, or metabolic characteristics. However, bottom-up synthetic biology also offers great potential to study subcellular structures like organelles. Because of their intricate and complex structure, these key elements of eukaryotic life forms remain poorly understood. Here, the controlled assembly of lipid enclosed, organelle-like architectures is explored by droplet-based microfluidics. Three types of giant unilamellar vesicles (GUVs)-based synthetic organelles (SOs) functioning within natural living cells are procedured: (A) synthetic peroxisomes supporting cellular stress-management, mimicking an organelle innate to the host cell by using analogous enzymatic modules; (B) synthetic endoplasmic reticulum (ER) as intracellular light-responsive calcium stores involved in intercellular calcium signalling, mimicking an organelle innate to the host cell but utilizing a fundamentally different mechanism; and (C) synthetic magnetosomes providing eukaryotic cells with a magnetotactic sense, mimicking an organelle that is not natural to the host cell but transplanting its functionality from other branches of the phylogenetic tree. Microfluidic assembly of functional SOs paves the way for high-throughput generation of versatile intracellular structures implantable into living cells. This in-droplet SO design may support or expand cellular functionalities in translational nanomedicine.

Abstract The engineering and modulation of living micro-organisms is a key challenge in green bio-manufacturing for the development of sustainable and carbon-neutral energy technologies. Here, we develop a cellular bionic approach in which living algal cells are interfaced with an ultra-thin shell of a conductive polymer along with a calcium carbonate exoskeleton to produce a discrete cellular micro-niche capable of sustained photosynthetic and photosynthetic-independent hydrogen production. The surface-augmented algal cells induce oxygen depletion, conduct photo-induced extracellular electrons, and provide structural and chemical stability that collectively give rise to localized hypoxic conditions and concomitant hydrogenase activity under daylight in air. We show that assembly of the living cellular micro-niche opens a direct extracellular photoelectron pathway to hydrogenase resulting in photosynthesis-independent hydrogen evolution for 200 d. In addition, surface-conductive dead algal cells continue to produce hydrogen for up to 8 d due to their structural stability and retention of functional hydrogenases. Overall, the integration of artificial biological hydrogen production pathways and natural photosynthesis in surface-augmented algal cells provides a cellular bionic approach to enhanced green hydrogen production under environmentally benign conditions and could pave the way to new opportunities in sustainable energy production.

Molecularly crowded coacervate micro-droplets are useful protocell constructs but the absence of a physical membrane limits their application as cytomimetic models. Auxiliary surface-active agents have been harnessed to stabilize the coacervate droplets by irreversible shell formation but endogenous processes of reversible membranization have received minimal attention. Herein, we describe a dynamic alginate/silk coacervate-based protocell model in which membrane-less droplets are reversibly reconfigured and inflated into semipermeable coacervate vesicles by spontaneous self-organization of amphiphilic silk polymers at the droplet surface under non-neutral charge conditions in the absence of auxiliary agents. We show that membranization can be reversibly controlled endogenously by programming the pH within the protocells using an antagonistic enzyme system such that structural reconfigurations in the protocell microstructure are coupled to the trafficking of water-soluble solutes. Our results open new perspectives in the design of hybrid protocell models with dynamical structural properties.

Polyelectrolyte/nucleotide multiphase complex coacervate droplets are produced by internalized aqueous two-phase separation and used for the spatially dependent chemical transfer of sugar molecules, providing a step towards the development of membrane-free "organelles" within coacervate-based protocells.